HLA- and genotype-based risk assessment model to identify infantile onset pompe disease patients at high-risk of developing significant anti-drug antibodies (ADA)
Recent Posts
- Dogs on Bicycles and Hamster (Proteins) in Biologics!
- Amsterdam Immunogenicity & Tolerance Seminar November 18, 2022 **Updated with Pictures!**
- EpiVax Joins Intravacc, CEPI on Project to Develop Universal Betacoronavirus Vaccine
- Tregs In SARS-COV-2? Yes, There Are. And: Boston, Basel And Amsterdam Oh My!
- AAPS PharmSci 360, October 16-19, 2022 **Updated with Pictures!**